Bausch targets India-based firm over IBS drug generic

Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bausch Ireland fends off challenge to its cancer patent

12 September 2023 Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

Americas

Bausch targets Israeli firm in skin treatment dispute

22 June 2023 Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Bausch targets India-based firm over IBS drug generic

More on this story

Editor's picks

Editor's picks

More features